600 related articles for article (PubMed ID: 24563870)
1. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
Golden EB; Demaria S; Schiff PB; Chachoua A; Formenti SC
Cancer Immunol Res; 2013 Dec; 1(6):365-72. PubMed ID: 24563870
[TBL] [Abstract][Full Text] [Related]
2. Immunologic correlates of the abscopal effect in a patient with melanoma.
Postow MA; Callahan MK; Barker CA; Yamada Y; Yuan J; Kitano S; Mu Z; Rasalan T; Adamow M; Ritter E; Sedrak C; Jungbluth AA; Chua R; Yang AS; Roman RA; Rosner S; Benson B; Allison JP; Lesokhin AM; Gnjatic S; Wolchok JD
N Engl J Med; 2012 Mar; 366(10):925-31. PubMed ID: 22397654
[TBL] [Abstract][Full Text] [Related]
3. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Formenti SC; Rudqvist NP; Golden E; Cooper B; Wennerberg E; Lhuillier C; Vanpouille-Box C; Friedman K; Ferrari de Andrade L; Wucherpfennig KW; Heguy A; Imai N; Gnjatic S; Emerson RO; Zhou XK; Zhang T; Chachoua A; Demaria S
Nat Med; 2018 Dec; 24(12):1845-1851. PubMed ID: 30397353
[TBL] [Abstract][Full Text] [Related]
5. Prospects for the use of ipilimumab in treating advanced prostate cancer.
Wei XX; Fong L; Small EJ
Expert Opin Biol Ther; 2016; 16(3):421-32. PubMed ID: 26698365
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Ansell SM; Hurvitz SA; Koenig PA; LaPlant BR; Kabat BF; Fernando D; Habermann TM; Inwards DJ; Verma M; Yamada R; Erlichman C; Lowy I; Timmerman JM
Clin Cancer Res; 2009 Oct; 15(20):6446-53. PubMed ID: 19808874
[TBL] [Abstract][Full Text] [Related]
8. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Small EJ; Tchekmedyian NS; Rini BI; Fong L; Lowy I; Allison JP
Clin Cancer Res; 2007 Mar; 13(6):1810-5. PubMed ID: 17363537
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.
Wilkins A; McDonald F; Harrington K; Melcher A
J Immunother Cancer; 2019 Mar; 7(1):64. PubMed ID: 30841910
[TBL] [Abstract][Full Text] [Related]
10. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Buchbinder EI; Desai A
Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
[TBL] [Abstract][Full Text] [Related]
13. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
[TBL] [Abstract][Full Text] [Related]
14. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
16. The Abscopal Effect in the Era of Checkpoint Inhibitors.
Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.
Rijavec E; Genova C; Barletta G; Burrafato G; Biello F; Dal Bello MG; Coco S; Truini A; Alama A; Boccardo F; Grossi F
Expert Opin Biol Ther; 2014 Jul; 14(7):1007-17. PubMed ID: 24702205
[TBL] [Abstract][Full Text] [Related]
18. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.
Wilgenhof S; Morlion V; Seghers AC; Du Four S; Vanderlinden E; Hanon S; Vandenbroucke F; Everaert H; Neyns B
Anticancer Res; 2012 Apr; 32(4):1355-9. PubMed ID: 22493370
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
